Clinical Outcomes After Personalized Dosimetry for 90Y Radioembolization of Advanced Hepatocellular Carcinoma: Defining the Role of a Device in a Pharma-Centric Landscape
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - February 1, 2024 Category: Nuclear Medicine Authors: Soulen, M. C., Rilling, W. S. Tags: INVITED PERSPECTIVE Source Type: research
Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trial
Conclusion: After longer follow-up, personalized dosimetry sustained a meaningful improvement in OS, which was dramatically improved for patients who were accurately downstaged toward resection, including most portal vein thrombosis patients. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - February 1, 2024 Category: Nuclear Medicine Authors: Garin, E., Tselikas, L., Guiu, B., Chalaye, J., Rolland, Y., de Baere, T., Assenat, E., Tacher, V., Palard, X., Deandreis, D., Mariano-Goulart, D., Amaddeo, G., Boudjema, K., Hollebecque, A., Meerun, M. A., Regnault, H., Vibert, E., Campillo-Gimenez, B., Tags: Clinical Investigations Source Type: research
Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network
Conclusion: This study confirms that 177Lu-DOTATATE PRRT does not lead to morphologic response on MMs (ORR < 5%). However, it allows MM stability, with few MM-related side effects, and has a relevant impact on MM-related symptoms. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - February 1, 2024 Category: Nuclear Medicine Authors: Al Mansour, L., De Mestier, L., Haissaguerre, M., Afchain, P., Hadoux, J., Lecomte, T., Morland, D., Cottereau, A. S., De Rycke, O., Tlili, G., Tordo, J., Janier, M., Deville, A., Walter, T. Tags: Clinical Investigations Source Type: research
Fibroblast Activation Protein {alpha}-Directed Imaging and Therapy of Solitary Fibrous Tumor
Conclusion: FAPα is highly expressed by SFT and may serve as a target for imaging and therapy. Further studies are warranted to define the role of FAPα-directed theranostics in the care of SFT patients. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - February 1, 2024 Category: Nuclear Medicine Authors: Hamacher, R., Pabst, K. M., Cheung, P. F., Heilig, C. E., Hullein, J., Liffers, S.-T., Borchert, S., Costa, P. F., Schaarschmidt, B. M., Kessler, L., Miera, M. A., Droste, M., Akbulut, M., Falkenhorst, J., Zarrad, F., Kostbade, K., Mavroeidi, I. A., Glimm Tags: Clinical Investigations Source Type: research
Beyond Average: {alpha}-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer
Conclusion: Primary patient data of radiopharmaceutical therapy distribution at the small scale revealed that 223Ra uptake is nonuniform. Dose estimates present both opportunities and challenges to enhance patient outcomes and are a first step toward personalized treatment approaches and improved understanding of α-particle radiopharmaceutical therapies. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - February 1, 2024 Category: Nuclear Medicine Authors: Benabdallah, N., Lu, P., Abou, D. S., Zhang, H., Ulmert, D., Hobbs, R. F., Gay, H. A., Simons, B. W., Saeed, M. A., Rogers, B. E., Jha, A. K., Tai, Y.-C., Malone, C. D., Ippolito, J. E., Michalski, J., Jennings, J. W., Baumann, B. C., Pachynski, R. K., Th Tags: FEATURED ARTICLE OF THE MONTH Source Type: research
Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study
Conclusion: Minimal tumor-absorbed dose at C1 is predictive of outcome in patients with GEP-NETs treated with PRRT, providing a basis for personalized dosimetry-guided treatment strategies. An SSTR TV decrease after C1 could be used for early therapy response assessment as a predictor of PRRT outcome. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - February 1, 2024 Category: Nuclear Medicine Authors: Mileva, M., Marin, G., Levillain, H., Artigas, C., Van Bogaert, C., Marin, C., Danieli, R., Deleporte, A., Picchia, S., Stathopoulos, K., Jungels, C., Vanderlinden, B., Paesmans, M., Ameye, L., Critchi, G., Taraji-Schiltz, L., Velghe, C., Wimana, Z., Bali Tags: Clinical Investigations Source Type: research
Peptide Receptor Radionuclide Therapy Is Effective for Clinical Control of Symptomatic Metastatic Insulinoma: A Long-Term Retrospective Analysis
Conclusion: To our knowledge, our study included the largest cohort of patients with malignant insulinoma to be evaluated. Long-lasting symptom control and reduction of antihypoglycemic medications were shown in most patients after late-line PRRT. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - February 1, 2024 Category: Nuclear Medicine Authors: Friebe, L., Freitag, M. T., Braun, M., Nicolas, G., Bauman, A., Bushnell, D., Christ, E., Wild, D. Tags: Clinical Investigations Source Type: research
Design Considerations in the PSMAfore Trial
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - February 1, 2024 Category: Nuclear Medicine Authors: Sartor, O., Fizazi, K., Herrmann, K., Morris, M. J. Tags: Editorials Source Type: research
The Imperative for Comparative Studies in Nuclear Medicine: Elevating 177Lu-PSMA-617 in the Treatment Paradigm for mCRPC
(Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - February 1, 2024 Category: Nuclear Medicine Authors: Rahbar, K., Boegemann, M. Tags: Editorials Source Type: research
Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16{alpha}-[18F]Fluoro-17{beta}-Estradiol PET
The estrogen receptor (ER), a steroid hormone receptor important in female physiology, is a significant contributor to breast carcinogenesis and progression and, as such, is an important therapeutic target. Approximately 70% of breast cancers will express ER at presentation, and the determination of ER expression by tissue assay, usually by immunohistochemistry, is part of the standard of care for newly diagnosed breast cancer. ER expression is important in guiding the approach to treatment, especially with the increase in relevant systemic therapies. The ER-targeting imaging agent 16α-[18F]fluoro-17β-estradiol ...
Source: Journal of Nuclear Medicine - February 1, 2024 Category: Nuclear Medicine Authors: Mankoff, D., Balogova, S., Dunnwald, L., Dehdashti, F., DeVries, E., Evangelista, L., Van Kruchten, M., Vaz, S. C., Fowler, A., Linden, H., Ulaner, G. A. Tags: PROCEDURE STANDARD Source Type: research
Value of 68Ga-FAPI-04 and 18F-FDG PET/CT in Early Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer
Conclusion: In this preliminary study, 68Ga-FAPI-04 PET change rate parameters were preferable to 18F-FDG in predicting pathologic response to NAC at an early stage in LAGC. 68Ga-FAPI %SUVmax and %TBR may be better predictors of therapeutic response between different treatment regimens. These findings may help optimize the treatment for patients with LAGC. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - February 1, 2024 Category: Nuclear Medicine Authors: Miao, Y., Feng, R., Yu, T., Guo, R., Zhang, M., Wang, Y., Hai, W., Shangguan, C., Zhu, Z., Li, B. Tags: Clinical Investigations Source Type: research
18F-FAPI-04 Outperforms 18F-FDG PET/CT in Clinical Assessments of Patients with Pancreatic Adenocarcinoma
Conclusion: 18F-FAPI-04 PET/CT performed better than 18F-FDG PET/CT in identification of primary tumors, LN metastasis, and DM and in TNM staging of PDAC. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - February 1, 2024 Category: Nuclear Medicine Authors: Li, X., Lu, N., Lin, L., Chen, Y., Yang, S., Wang, H., Liu, X., Wu, C., Xue, X., Su, X., Bai, X., Liang, T. Tags: Clinical Investigations Source Type: research
Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer
Conclusion: 68Ga-FAP-2286 imaging is highly sensitive in patients with urothelial cancer and is effective in identifying metastatic lesions across a variety of anatomic sites, including subcentimeter lymph nodes that would not have raised suspicion on conventional scans. This novel imaging modality may inform clinical decision-making in patients with MIBC both by refining local nodal staging and by defining metastatic disease that would otherwise be undetectable on conventional imaging. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - February 1, 2024 Category: Nuclear Medicine Authors: Koshkin, V. S., Kumar, V., Kline, B., Escobar, D., Aslam, M., Cooperberg, M. R., Aggarwal, R. R., de Kouchkovsky, I., Chou, J., Meng, M. V., Friedlander, T., Porten, S., Hope, T. A. Tags: Clinical Investigations Source Type: research
Diagnostic Performance of [18F]TFB PET/CT Compared with Therapeutic Activity [131I]Iodine SPECT/CT and [18F]FDG PET/CT in Recurrent Differentiated Thyroid Carcinoma
Conclusion: Pretherapeutic [18F]TFB PET/CT may help to predict the positivity of recurrent DTC lesions on [131I]iodine scans. Therefore, it may help in the selection of patients for [131I]iodine therapy. Future prospective trials for iodine therapy guidance are warranted. Lesion [18F]TFB uptake seems to be inversely correlated with [18F]FDG uptake and therefore might serve as a dedifferentiation marker in DTC. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - February 1, 2024 Category: Nuclear Medicine Authors: Ventura, D., Dittmann, M., Buther, F., Schafers, M., Rahbar, K., Hescheler, D., Claesener, M., Schindler, P., Riemann, B., Seifert, R., Roll, W. Tags: Clinical Investigations Source Type: research
[18F]FDG PET/CT-Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Study
Conclusion: TDV is a potential prognostic biomarker in GEPNENs and should be investigated in future neuroendocrine neoplasm trials. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - February 1, 2024 Category: Nuclear Medicine Authors: Chan, D. L., Hayes, A. R., Karfis, I., Conner, A., Mileva, M., Bernard, E., Schembri, G., Navalkissoor, S., Gnanasegaran, G., Pavlakis, N., Marin, C., Vanderlinden, B., Flamen, P., Roach, P., Caplin, M. E., Toumpanakis, C., Bailey, D. L. Tags: Clinical Investigations Source Type: research
